Pharmaceutical Research and Manufacturers of America
GPTKB entity
Statements (137)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Trade_Federation
|
| gptkbp:advocates_for |
gptkb:healthcare_access
patient rights patient-centered care research funding intellectual property rights evidence-based medicine public policies healthcare reforms regulatory reform affordable medicines research transparency research investment biopharmaceutical innovation patient access drug affordability fair pricing of drugs healthcare innovation policies |
| gptkbp:collaborates_with |
government agencies
non-profit organizations academic institutions healthcare systems government health programs clinical research organizations patient care organizations |
| gptkbp:conducts |
research initiatives
advocacy campaigns |
| gptkbp:engages_in |
gptkb:health_services
social media stakeholders community outreach international organizations research institutions community health organizations lobbying healthcare policy discussions public health campaigns public relations media relations healthcare technology companies stakeholder dialogues healthcare stakeholders |
| gptkbp:focus |
pharmaceutical research
|
| gptkbp:founded |
gptkb:1958
|
| gptkbp:has_a_website |
www.phrma.org
|
| gptkbp:has_mission |
advance medical innovation
|
| gptkbp:has_partnerships_with |
academic institutions
|
| gptkbp:has_role |
shaping healthcare policy
shaping drug policy |
| gptkbp:headquartered_in |
gptkb:the_United_States
|
| gptkbp:headquarters |
gptkb:Washington,_D._C.
|
| gptkbp:hosts |
conferences
webinars |
| https://www.w3.org/2000/01/rdf-schema#label |
Pharmaceutical Research and Manufacturers of America
|
| gptkbp:influences |
gptkb:legislation
|
| gptkbp:initiatives |
diversity in clinical trials
|
| gptkbp:is_a_member_of |
gptkb:International_Federation_of_Pharmaceutical_Manufacturers_&_Associations
|
| gptkbp:is_a_resource_for |
gptkb:healthcare_professionals
healthcare data |
| gptkbp:is_a_source_of |
industry statistics
|
| gptkbp:is_committed_to |
patient safety
research transparency |
| gptkbp:is_focused_on |
innovation in drug development
sustainable healthcare solutions |
| gptkbp:is_involved_in |
gptkb:Health_Insurance
gptkb:healthcare_reform patient advocacy international collaborations global health initiatives drug safety initiatives drug pricing discussions |
| gptkbp:is_known_for |
advocacy efforts
|
| gptkbp:is_recognized_for |
contributions to public health
|
| gptkbp:key_player |
the pharmaceutical industry
|
| gptkbp:leadership |
pharmaceutical advocacy.
|
| gptkbp:member |
industry leaders
|
| gptkbp:members |
pharmaceutical companies
|
| gptkbp:offers |
gptkb:educational_programs
gptkb:educational_resources |
| gptkbp:participates_in |
industry conferences
|
| gptkbp:promotes |
gptkb:biotechnology
gptkb:scientific_research innovation in drug development access to medicines sustainable healthcare solutions patient access to medicines |
| gptkbp:provides |
research and data
policy analysis guidance on regulations information on drug approvals resources for policymakers guidance on clinical practices information on drug pricing insights on market access data on drug development costs data on healthcare outcomes data on pharmaceutical spending information on drug development timelines information on drug safety standards insights on pharmaceutical trends resources for drug manufacturers |
| gptkbp:provides_guidance_on |
regulatory issues
|
| gptkbp:provides_information_on |
gptkb:healthcare_access
market trends drug development |
| gptkbp:provides_support_for |
biotechnology companies
healthcare research |
| gptkbp:publishes |
annual reports
|
| gptkbp:represents |
biopharmaceutical industry
|
| gptkbp:supports |
patient education
clinical trials public health initiatives research funding healthcare policies research funding initiatives global health initiatives patient education programs healthcare innovation research collaborations drug safety initiatives health equity initiatives drug discovery efforts emerging therapies patient safety programs clinical research funding. drug access programs |
| gptkbp:was_a_proponent_of |
evidence-based medicine
|
| gptkbp:works_with |
stakeholders
healthcare providers insurance companies regulatory bodies patient advocacy groups medical associations |
| gptkbp:bfsParent |
gptkb:Robert_Wood_Johnson
gptkb:Ph_RMA gptkb:H._R._3 |
| gptkbp:bfsLayer |
5
|